An interventional study of Defibrillation (RV Implant) and Defibrillation (LBBAP Implant) in Ventricular Tachyarrhythmia, sponsored by Medtronic Cardiac Rhythm and Heart Failure. Completed at 55 sites in 20 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Medtronic Cardiac Rhythm and Heart Failure (part of Medtronic) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Tachycardia, Ventricular by Medtronic — 2 open to participants now, 4 under way, none of them phase 3. Tachycardia, Ventricular · Medtronic.
Among the 19 studies in Tachycardia, Ventricular by Medtronic, this one has the largest enrollment of the 10 interventional ones that give a count, is the only one that started in 2021, is one of 7 with no phase, and was the 16th registered.
452 studies on the registry are indexed under Tachycardia, Ventricular; 121 are open to participants now.
Browse Tachycardia, Ventricular studies →2 of the 19 studies in Tachycardia, Ventricular by Medtronic are open now, in 1 country. Recruiting first, the newest first:
Medtronic Cardiac Ablation Solutions · Sites in United States
Ages 18–85
Medtronic Cardiac Ablation Solutions · Sites in United States
Ages 18–85
By country, each count listing its studies:
Of the 86 Tachycardia, Ventricular studies recruiting now, 67 (78%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 5 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 1 started in 2021.
This study's enrollment of 1,007 is above the median of 70 across 281 interventional studies indexed under Tachycardia, Ventricular.
Median enrollment 307 across the 10 interventional studies, 1,326 across the 9 observational. Of the 15 that completed or were terminated, 7 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Medtronic Cardiac Rhythm and Heart Failure, one of the names counted as Medtronic. Under that name alone:
Medtronic Cardiac Rhythm and Heart Failure is the lead sponsor of 240 studies on the registry; 4 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 18 (95%) have results posted.
1 of the studies in Tachycardia, Ventricular by Medtronic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06703489Medtronic Cardiac Ablation SolutionsSafety and Performance Assessment of the Sphere-9™ Catheter and Affera™ Ablation System for the Treatment of Ventricular Tachycardia (Sphere-9 VT EFS) | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies in Tachycardia, Ventricular by Medtronic, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The LEADR study is designed to assess the safety and efficacy of the Next Generation ICD lead.
The LEADR LBBAP study is being conducted under the existing US FDA Investigational Device Exemption (IDE) for the Next Generation ICD Lead and is designed to confirm the safety and defibrillation efficacy of the Next Generation ICD Lead when placed in the LBBAP location in ICD and LOT-CRT patient population.
The LEADR and LEADR LBBAP studies will enroll subjects who are indicated to receive an implantable single or dual chamber ICD, or CRT-D, and who meet all of the inclusion criteria and none of the exclusion criteria. Subjects will receive an investigational Next Generation ICD Lead. Subjects in the LEADR study will be followed for at least 18 months following Next Generation ICD Lead implantation in a septal (non-LBBAP) or apical implant location. Enrollment in the LEADR study has been completed (675 subjects enrolled). Subjects in the LEADR LBBAP study will be followed for at least 3 months (ICD-indicated subjects) or 6 months (CRT-indicated subjects) following Next Generation ICD Lead implantation in an LBBAP implant location. Enrollment in the LEADR LBBAP study has been completed (332 subjects enrolled).
LEADR Inclusion Criteria:
Subject meets current clinical practice guidelines for implantation of ICD or CRT-D and will undergo one of the following:
LEADR Exclusion Criteria:
For subject undergoing defibrillation testing the following medical conditions exclude them:
LEADR LBBAP Inclusion Criteria:
Subject meets current local clinical practice guidelines for implantation of ICD (single or dual chamber) or CRT-D system and will undergo one of the following:
a) De novo Medtronic ICD system implant (single or dual chamber) or b) De novo Medtronic CRT-D system implant and is intended to also undergo LV lead implant (for patients indicated for CRT-D according to locally approved indications/indications)
LEADR LBBAP Exclusion Criteria:
For subject undergoing defibrillation testing the following medical conditions exclude them:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will be implanted with a Next Generation ICD Lead and undergo required electrical testing
Device: Defibrillation (RV Implant)
Patients will be implanted with a Next Generation ICD Lead in the LBBAP location and undergo required electrical testing
Device: Defibrillation (LBBAP Implant)
Required electrical testing for pacing, sensing, impedance and defibrillation will be completed
Required electrical testing for pacing, sensing, impedance and defibrillation will be completed
LEADR: Estimate the Rate of Major Lead Complication-free Rate at 6 Months
Subjects free of Next Generation ICD lead-related complication at 6 months post-implant.
Time frame: Implant to 6 Months
LEADR: Percentage of Subjects Successfully Defibrillated at Implant With the Next Generation ICD Lead
Defibrillation testing will be completed in a subset of subjects at implant.
Time frame: Day 1
LEADR LBBAP: Percentage of Subjects Successfully Defibrillated at Implant With the Next Generation ICD Lead
Defibrillation testing will be completed with the Next Generation ICD Lead in the LBBAP location in a subset of subjects at implant.
Time frame: Day 1
LEADR LBBAP: The Lead-related Major Complication Rate at 3-months
Subjects free of Next Generation ICD lead-related complication at 3 months post-implant.
Time frame: Implant to 3 Months
LEADR: Estimate the Fracture-free Rate of the Next Generation ICD Lead
Subjects will be assessed at certain time points for Next Generation ICD lead fracture related to the Next Generation ICD lead.
Time frame: up to 18 months
For LEADR, the first clinical study subject was enrolled on 21-Jun-2021. Enrollments and implants were considered to be completed on 01-Nov-2022. The first two LEADR LBBAP clinical study subjects were enrolled on 19-Apr-2024, with enrollments and implants being complete on 27-May-2025.
| Milestone | Intervention/Treatment (LEADR) | Intervention/Treatment (LEADR LBBAP) |
|---|---|---|
| Started | 675 | 332 |
| Completed | 513 | 277 |
| Not completed | 162 | 55 |
Subjects free of Next Generation ICD lead-related complication at 6 months post-implant.
| Participants | Intervention/Treatment (LEADR) | Intervention/Treatment (LEADR LBBAP) |
|---|---|---|
| LEADR: Estimate the Rate of Major Lead Complication-free Rate at 6 Months | 638 | — |
Defibrillation testing will be completed in a subset of subjects at implant.
| % subjects succesfully defibrillated | Intervention/Treatment (LEADR) | Intervention/Treatment (LEADR LBBAP) |
|---|---|---|
| LEADR: Percentage of Subjects Successfully Defibrillated at Implant With the Next Generation ICD Lead | 95.8 | — |
Defibrillation testing will be completed with the Next Generation ICD Lead in the LBBAP location in a subset of subjects at implant.
| % subjects succesfully defibrillated | Intervention/Treatment (LEADR) | Intervention/Treatment (LEADR LBBAP) |
|---|---|---|
| LEADR LBBAP: Percentage of Subjects Successfully Defibrillated at Implant With the Next Generation ICD Lead | — | 100 |
Subjects free of Next Generation ICD lead-related complication at 3 months post-implant.
| Participants | Intervention/Treatment (LEADR) | Intervention/Treatment (LEADR LBBAP) |
|---|---|---|
| LEADR LBBAP: The Lead-related Major Complication Rate at 3-months | — | 310 |
Subjects will be assessed at certain time points for Next Generation ICD lead fracture related to the Next Generation ICD lead.
| Participants | Intervention/Treatment (LEADR) | Intervention/Treatment (LEADR LBBAP) |
|---|---|---|
| LEADR: Estimate the Fracture-free Rate of the Next Generation ICD Lead | 656 | — |
Collected over From enrollment until end of follow-up. For LEADR the average (SD) follow up was 31.7 (10.1) months. For LEADR LBBAP the average (SD) follow up was 9.9 (4) months.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Intervention/Treatment (LEADR) | 63/675 (9.3%) | 394/675 (58.4%) | 412/675 (61%) |
| Intervention/Treatment (LEADR LBBAP) | 8/332 (2.4%) | 119/332 (35.8%) | 143/332 (43.1%) |
| Event | Intervention/Treatment (LEADR) | Intervention/Treatment (LEADR LBBAP) |
|---|---|---|
| Ventricular tachycardiaCardiac disorders | 59/675 | 12/332 |
| Atrial fibrillationCardiac disorders | 54/675 | 15/332 |
| Cardiac failureCardiac disorders | 46/675 | 16/332 |
| Cardiac failure congestiveCardiac disorders | 23/675 | 3/332 |
| PneumoniaInfections and infestations | 23/675 | 5/332 |
| Atrioventricular block completeCardiac disorders | 2/675 | 11/332 |
| Device inappropriate shock deliveryProduct issues | 22/675 | 5/332 |
| Lead dislodgementProduct issues | 21/675 | 6/332 |
| Acute kidney injuryRenal and urinary disorders | 20/675 | 7/332 |
| HypotensionVascular disorders | 19/675 | 3/332 |
| Event | Intervention/Treatment (LEADR) | Intervention/Treatment (LEADR LBBAP) |
|---|---|---|
| Ventricular tachycardiaCardiac disorders | 127/675 | 22/332 |
| Atrial fibrillationCardiac disorders | 50/675 | 10/332 |
| COVID-19Infections and infestations | 47/675 | 4/332 |
| DizzinessNervous system disorders | 26/675 | 5/332 |
| FatigueGeneral disorders and administration site conditions | 24/675 | 6/332 |
| Cardiac failureCardiac disorders | 21/675 | 4/332 |
| Device pacing issueProduct issues | 21/675 | 3/332 |
| Device stimulation issueProduct issues | 4/675 | 10/332 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 19/675 | 4/332 |
| Cardiac perforationCardiac disorders | 0/675 | 9/332 |
| Age, Continuous(years) | Intervention/Treatment (LEADR) | Intervention/Treatment (LEADR LBBAP) | Total |
|---|---|---|---|
| Mean | 61.9 ± 13 | 64.9 ± 12.2 | 62.8 ± 12.8 |
| Sex: Female, Male(Participants) | Intervention/Treatment (LEADR) | Intervention/Treatment (LEADR LBBAP) | Total |
|---|---|---|---|
| Female | 174 | 96 | 270 |
| Male | 489 | 231 | 720 |
| Race (NIH/OMB)(Participants) | Intervention/Treatment (LEADR) | Intervention/Treatment (LEADR LBBAP) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 2 |
| Asian | 39 | 2 | 41 |
| Native Hawaiian or Other Pacific Islander | 2 | 0 | 2 |
| Black or African American | 54 | 21 | 75 |
| White | 241 | 144 | 385 |
| More than one race | 2 | 0 | 2 |
| Unknown or Not Reported | 336 | 164 | 500 |
| Ethnicity (NIH/OMB)(Participants) | Intervention/Treatment (LEADR) | Intervention/Treatment (LEADR LBBAP) | Total |
|---|---|---|---|
| Hispanic or Latino | 23 | 3 | 26 |
| Not Hispanic or Latino | 234 | 149 | 383 |
| Unknown or Not Reported | 418 | 180 | 598 |
| Region of Enrollment(Participants) | Intervention/Treatment (LEADR) | Intervention/Treatment (LEADR LBBAP) | Total |
|---|---|---|---|
| Singapore | 6 | 0 | 6 |
| Hong Kong | 32 | 11 | 43 |
| United States | 270 | 154 | 424 |
| Japan | 33 | 17 | 50 |
| United Kingdom | 10 | 4 | 14 |
| Malaysia | 45 | 30 | 75 |
| Portugal | 10 | 0 | 10 |
| Spain | 18 | 5 | 23 |
| Canada | 68 | 24 | 92 |
| Austria | 10 | 0 | 10 |
| Netherlands | 0 | 6 | 6 |
| Belgium | 0 | 8 | 8 |
| China | 22 | 17 | 39 |
| Denmark | 6 | 0 | 6 |
| Poland | 0 | 9 | 9 |
| Italy | 22 | 0 | 22 |
| Australia | 58 | 35 | 93 |
| France | 20 | 12 | 32 |
| Serbia | 22 | 0 | 22 |
| Germany | 23 | 0 | 23 |
| Height(centimeters) | Intervention/Treatment (LEADR) | Intervention/Treatment (LEADR LBBAP) | Total |
|---|---|---|---|
| Mean | 171.3 ± 10.5 | 171.1 ± 10.4 | 171.2 ± 10.5 |
| Weight(kilograms) | Intervention/Treatment (LEADR) | Intervention/Treatment (LEADR LBBAP) | Total |
|---|---|---|---|
| Mean | 84.1 ± 22.3 | 83.7 ± 21.4 | 84.0 ± 22.0 |
| BMI(kg/m^2) | Intervention/Treatment (LEADR) | Intervention/Treatment (LEADR LBBAP) | Total |
|---|---|---|---|
| Mean | 28.5 ± 6.3 | 28.4 ± 6.1 | 28.5 ± 6.3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2021 to primary completion in Sep 2025, 50 months.
Results were first posted in Nov 2026, 1 year 2 months after primary completion.
Of 40 industry-sponsored interventional studies with no phase under Tachycardia, Ventricular, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 52. This study's 50 months is above that.
Counting every sponsor, half of 126 studies reached it within 36 months; a quarter within 20 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medtronic Cardiac Rhythm and Heart Failure →